Phase 1 study of NB003, a broad-spectrum KIT/PDGFRα inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST).

被引：0
|
作者：
Li, Jian
Chi, Ping
Kang, Yoon-Koo
Cao, Hui
George, Suzanne
Zhang, Jun
Zhang, Jian
Hu, Kang
Zhang, Lijia
Xu, Yanhua
机构：
[1] Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst,Minist Educ, Lab Carcinogenesis & Translat Res,Dept Gastrointe, Beijing, Peoples R China
[2] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
[3] Univ Ulsan, Dept Oncol, Asan Med Ctr, Seoul, South Korea
[4] Shanghai Jiao Tong Univ, Renji Hosp, Dept Gastrointestinal Surg, Sch Med, Shanghai, Peoples R China
[5] Dana Farber Canc Inst, Dept Med Oncol, Sarcoma Ctr, Boston, MA USA
[6] Chongqing Med Univ, Dept Gastroenterol, Affiliated Hosp 1, Chongqing, Peoples R China
[7] Fudan Univ, Dept Med Oncol, Phase 1 Clin Trial Ctr, Shanghai Canc Hosp, Shanghai, Peoples R China
[8] Ningbo Newbay Technol Dev Co Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11518
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Clinicopathological significance of the c-KIT and PDGFRα gene mutations in patients with localized gastrointestinal stromal tumors:: A study of the Spanish research sarcoma group (GEIS)
    Llombart-Bosch, A
    Lopez-Guerrero, J
    Calabuig, S
    Martin, J
    Ramos, R
    Ortega, L
    Pellin, A
    MODERN PATHOLOGY, 2005, 18 : 111A - 111A
  • [32] A phase I study of nilotinib alone and in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors (GIST): Study update
    Blay, J. Y.
    Casali, P. G.
    Reichardt, P.
    von Mehren, M.
    Debiec-Rychter, M.
    Bailey, S.
    Veronese, M. L.
    Demetri, G. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [33] Phase II Study of Cediranib in Patients with Advanced Gastrointestinal Stromal Tumors or Soft-Tissue Sarcoma
    Judson, Ian
    Scurr, Michelle
    Gardner, Kate
    Barquin, Elizabeth
    Marotti, Marcelo
    Collins, Barbara
    Young, Helen
    Juergensmeier, Juliane M.
    Leahy, Michael
    CLINICAL CANCER RESEARCH, 2014, 20 (13) : 3603 - 3612
  • [34] Phase II study of paclitaxel in patients with advanced gastrointestinal stromal tumor (GIST) after failure of at least both imatinib and sunitinib
    Cho, H.
    Ryu, M-H.
    Kim, B. J.
    Park, Y.
    Na, Y-S.
    Ma, J.
    Beck, M. Y.
    Kang, Y-K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [35] Phase Ib study of rapid alternation of sunitinib (SU) and regorafenib (RE) in patients (pts) with advanced gastrointestinal stromal tumor (GIST).
    Serrano, Cesar
    Leal, Alessandro
    Phallen, Jillian
    Marino-Enriquez, Adrian
    Kuang, Yanan
    Triplett, Olivia
    Morgan, Jeffrey A.
    Barysauskas, Constance
    Wagner, Andrew J.
    Demetri, George D.
    Velculescu, Victor E.
    Paweletz, Cloud
    Fletcher, Jonathan A.
    George, Suzanne
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [36] Initial results from the phase (ph) 1 portion of a ph 1/2 study of THE-630 in patients (pts) with advanced gastrointestinal stromal tumor (GIST)
    George, Suzanne
    Tap, William D.
    von Mehren, Margaret
    Gordon, Michael S.
    Trent, Jonathan C.
    Attia, Steven
    Zhang, Sen
    Narasimhan, Narayana
    Rivera, Victor M.
    Kerstein, David
    Heinrich, Michael C.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [37] A phase I study of nilotinib alone and in combination with imatinib in patients (PTS) with imatinib-resistant gastrointestinal stromal tumors (GIST) -: Study update
    Reichardt, Peter
    Casali, Paolo G.
    Blay, Jean-Yves
    von Mehren, Margaret
    Schoffski, Patrick
    Tanaka, Chiaki
    Jalaluddin, Muhammad
    Veronese, Maria Luisa
    Demetri, George D.
    ANNALS OF ONCOLOGY, 2006, 17 : 138 - 138
  • [38] A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PLX9486 alone and in combination (combo) with the KIT inhibitors pexidartinib (pexi) or sunitinib (su) in patients (Pts) with advanced solid tumors and gastrointestinal stromal tumor (GIST).
    Wagner, Andrew J.
    Tap, William D.
    Shields, Anthony Frank
    Patnaik, Amita
    Chugh, Rashmi
    Tinoco, Gabriel
    Michelson, Glenn
    Alcantar, Oscar
    Pelayo, Michael
    Zhang, Chao
    Severson, Paul
    Martin, Eric
    Trent, Jonathan C.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [39] Clinical efficacy of avapritinib in gastrointestinal stromal tumors (GIST) with different KIT genotypes: Post hoc analysis of the phase 1 NAVIGATOR and phase 1/2 CS3007-101 trials
    Heinrich, Michael C.
    Li, Jian
    Zhang, Xinhua
    Jones, Robin L.
    George, Suzanne
    Trent, Jonathan C.
    Serrano, Cesar
    Deng, Yanhong
    Bauer, Sebastian
    Cai, Shirong
    Wu, Xin
    Zhou, Yongjian
    Tao, Kaixiong
    Zheng, Zhichao
    Zhang, Jun
    Cui, Yuehong
    Cao, Hui
    Wang, Meining
    Hu, Jin
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [40] Exploratory analysis of tumor growth rate in patients (pts) with advanced gastrointestinal stromal tumors (GIST) treated with regorafenib (REG) in the GRID phase 3 trial
    Kappeler, C.
    Reichardt, P.
    Kong, Y. -K.
    Blay, J. -Y.
    Joensuu, H.
    Schaefer, K.
    Chung, J.
    Wagner, A.
    Cosali, P. G.
    Demetri, G.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 144 - 145
12345